Patel, Hetal <br/><br/>
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.  [electronic resource] 

 -  Molecular cancer therapeutics  06 2018 
 - 1156-1166 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-16-0847  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Biological Availability<br/>Caspases--metabolism<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Mice<br/>Phosphorylation<br/>Protein Kinase Inhibitors--administration & dosage<br/>Xenograft Model Antitumor Assays<br/>Cyclin-Dependent Kinase-Activating Kinase